Vivos Therapeutics Files 8-K for Financial Update
Ticker: VVOS · Form: 8-K · Filed: Apr 15, 2026
Sentiment: neutral
Topics: financial-results, 8-k, exhibits
TL;DR
Vivos Therapeutics dropped an 8-K on 4/15/26 detailing financial results and exhibits.
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on April 15, 2026, reporting on its Results of Operations and Financial Condition. The filing also includes Financial Statements and Exhibits. Specific financial details and performance metrics are expected to be found within the attached exhibits.
Why It Matters
This filing provides investors with crucial updates on Vivos Therapeutics' financial performance and condition, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful review.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Filer of the 8-K
- 0001716166 (company) — CIK number for Vivos Therapeutics, Inc.
- 0001493152-26-016865 (filing_id) — SEC Accession Number for the 8-K filing
- 2026-04-15 (date) — Filing Date and Period of Report
FAQ
What specific financial results are reported in this 8-K filing?
The filing indicates Item 2.02: Results of Operations and Financial Condition, suggesting financial results are reported, but specific figures are detailed in the accompanying exhibits.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-15 at 17:15:08.
What are the main items covered in this 8-K filing?
The main items are Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Where is Vivos Therapeutics, Inc. located based on the filing?
The mailing and business address listed is 7921 SOUTHPARK PLAZA, SUITE 210 LITTLETON CO 80120.
What is the SIC code for Vivos Therapeutics, Inc.?
The SIC code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2026 regarding Vivos Therapeutics, Inc. (VVOS).